Search - tctmd.com

Displaying 101 - 120 of 204

Sort: Relevancy | Date

News Daily News

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Yael L. Maxwell

April 16, 2025

News Daily News

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

L.A. McKeown

April 15, 2025

News Daily News

Cardiotoxicity Rare With Common GI Chemotherapy

L.A. McKeown

April 15, 2025

News Daily News

High BMI Before Pregnancy Tied to Greater CVD Risk Later in Life

L.A. McKeown

April 14, 2025

News Daily News

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Caitlin E. Cox

April 14, 2025

News Daily News

Weekend Warriors Also See Mortality Benefits With Exercise

Michael O'Riordan

April 10, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Daily News

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

Michael O'Riordan

April 09, 2025

News Daily News

AHA Tackles Need for Increased CV Prevention in Emerging Adults

Yael L. Maxwell

April 09, 2025

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

News Conference News EHRA 2025

Sudden Cardiac Death Risk Linked to Long-term Antidepressant Use

Todd Neale

April 01, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2025

Caitlin E. Cox

April 01, 2025

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

Presentation ACC 2025

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Presenter: Luke Laffin

March 29, 2025

Presentation ACC 2025

Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients with Coagulopathy—Results from a Phase 3, Randomized, Active-Control Study

Presenter: Keyvan Karkouti

March 29, 2025

News Daily News

Risk of Another Event Remains High for Years After TIA, Minor Stroke

Todd Neale

March 26, 2025

Advertisement

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

Cardiotoxicity Rare With Common GI Chemotherapy

High BMI Before Pregnancy Tied to Greater CVD Risk Later in Life

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Weekend Warriors Also See Mortality Benefits With Exercise

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

AHA Tackles Need for Increased CV Prevention in Emerging Adults

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Sudden Cardiac Death Risk Linked to Long-term Antidepressant Use

TCTMD’s Top 10 Most Popular Stories for March 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients with Coagulopathy—Results from a Phase 3, Randomized, Active-Control Study

Risk of Another Event Remains High for Years After TIA, Minor Stroke

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content